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have no additional conflicts of interest to disclose in this project. When fulfilled in patients with IgE-dependent allergic reactions or other reactive processes, 81 the term applied is secondary MCAS (Table 1) (1,2). When no underlying etiology is 82 identified, the diagnosis is idiopathic MCAS (2). MCAS criteria are widely accepted and have 83 been validated in specific situations (5). 84
The diagnosis of MCAS is currently being applied to patients with unresolved complex 85 medical problems following extensive medical evaluations, and a substantial number of these 86 patients do not meet the diagnostic criteria for MCAS. Once the referral center providers 87 eliminate diseases in the differential diagnosis, they find they have little to add in the way of 88 providing a satisfactory response or therapy as no MCAS is found. In other cases, an 89 underlying disease unrelated to MCAS is (later) detected, and an unnecessary delay of such 90 a diagnosis may be a consequence of the ´MCAS-referral´. 91
Finally, the suggestion to patients that they have a MC disorder beyond (or in addition to) 92 MCAS is not without consequences. Suggestion of a MC disorder may lead to unjustified 93 anxiety and fear for patients, especially when the concept of MCAS is understood as 94 synonymous to systemic mastocytosis, which can lead to hematological malignancy. 95
Moreover, in those without typical clinical symptoms, there may be increased costs and 96 health care utilization in an effort to implicate MCs in pathology. The solution to this emerging problem, we suggest, is four-fold. First, caution is needed in 107 applying the diagnosis of MCAS; and consensus criteria should be met (1, 2) . MCAS should 108 not be applied on the basis of a persistently elevated basal serum tryptase level and not on 109 the fact that the condition has resisted previous attempts to establish a medical diagnosis. 110
Secondly, if the diagnosis is applied, referral centers must be prepared to evaluate these 111 individuals and eliminate diseases in the differential diagnosis. It is important to recognize 112 that other pathologic conditions, including sepsis, cytokine storm associated with 113 administration of biologics, acute intoxication, poisoning, and endocrinology emergencies 114 may mimic MCAS (2). And in those with elevated basal tryptase, diverse hematologic 115 neoplasms, chronic inflammation or familial tryptasemia may be detected (2). Third, referral 116 centers must implement a follow-up plan for monitoring and care of these patients and/or 117 until a research protocol is in place to understand the difficulties that lead to this diagnosis. 118
Fourth, clinical research programs are needed to explore the possibility that there are yet to 119 be defined MC activation disorders. Such studies need to evaluate the consensus criteria for 120 MCAS. Strategies need to be in place to identify specific phenotypes/endotypes with 121 underlying genetic variants that will lead to uniform diagnostic approaches. Interventional One example is histamine or its metabolites when measured in urine, although histamine is 131 produced by MC and basophils. Measurement of tryptase in bodily fluids is more specific and 132 is generally considered the most reliable diagnostic test of MC involvement and thus strongly 133 recommended within consensus diagnostic criteria (1-2,7) . Prostaglandin D2 and histamine 134 metabolite levels in urine can both increase over baseline in MCAS and have also been 135 measured and used as guide for treatment (8) , although their elevation may not always be 136 
